Matthew Biegler
Stock Analyst at Oppenheimer
(3.36)
# 1,017
Out of 5,128 analysts
88
Total ratings
37.97%
Success rate
7.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $27.07 | +77.32% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $28.22 | +59.46% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $8.68 | +72.81% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $12.10 | +81.89% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $18.49 | +51.43% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $2.95 | +171.19% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $4.30 | +62.79% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.49 | +504.03% | 2 | May 14, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $160 | $13.56 | +1,079.94% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $12.41 | +262.61% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $124.35 | -7.52% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $37.86 | +39.99% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $30.13 | +9.53% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.42 | +726.45% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.18 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $7.76 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.98 | +40.28% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.30 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.11 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $9.61 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.06 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.24 | - | 2 | Dec 22, 2022 |
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $27.07
Upside: +77.32%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $28.22
Upside: +59.46%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $8.68
Upside: +72.81%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $12.10
Upside: +81.89%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $18.49
Upside: +51.43%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $2.95
Upside: +171.19%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $4.30
Upside: +62.79%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.49
Upside: +504.03%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $13.56
Upside: +1,079.94%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $12.41
Upside: +262.61%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $124.35
Upside: -7.52%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $37.86
Upside: +39.99%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $30.13
Upside: +9.53%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.42
Upside: +726.45%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $8.18
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $7.76
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $9.98
Upside: +40.28%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.30
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.11
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $9.61
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.06
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.24
Upside: -